
Real-world Evidence Team
Group description
We develop, validate and implement methods and approaches for evaluating effectiveness and safety of treatments by using real-world data, and also work on risk factors for conditions with long onset period.
The applied data ranges from national register-based studies to multi- and single-centre studies using data from electronic medical records and medical reports as well as data collected specifically for research purposes.
The applied methods range from traditional statistical methods to machine learning. We work in close collaboration with clinicians and have extensive collaboration network, both nationally (e.g., VTT, THL, University of Turku and University of Oulu) and internationally (e.g., Hong Kong University, Monash University, Karolinska Institutet) .
We belong to the SIGMA Consortium of ENCePP research centres, that aims to provide trusted pharmacoepidemiologic and real-world evidence research through a European federated professional network of excellence.
Our work is primarily focused on Alzheimer’s disease and Parkinson’s disease, and we coordinate nationwide registe
Keywords
Publications
38 items-
Antipsychotic Use and Risk of Stroke Among Community-Dwelling People With Alzheimer's Disease
Koponen, Marjaana; Rajamaki, Blair; Lavikainen, Piia; Bell, J Simon; Taipale, Heidi; Tanskanen, Antti; Hartikainen, Sirpa; Tolppanen, Anna-Maija. 2022. Journal of the american medical directors association. 23: 1059-1065 -
Coronary artery revascularizations and cognitive decline - A systematic review
Lappalainen, Laura; Rajamaki, Blair; Tolppanen, Anna-Maija; Hartikainen, Sirpa. 2022. Current problems in cardiology. 47: -
Association of recent hospitalisation with antidepressant initiation among community dwellers with Alzheimer's disease
Tarvainen, Anniina; Hartikainen, Sirpa; Taipale, Heidi; Tanskanen, Antti; Koponen, Marjaana; Tolppanen, Anna-Maija. 2021. International journal of geriatric psychiatry. 36: 1075-1084 -
Automated multi-dose dispensing in persons with and without Alzheimer's disease - impacts on pharmacotherapy
Vallius, Sanna; Taipale, Heidi; Koponen, Marjaana; Tolppanen, Anna-Maija; Tanskanen, Antti; Hartikainen, Sirpa; Tiihonen, Miia. 2021. European journal of clinical pharmacology. 2022; 78: 513-521 -
Coronary Revascularization and Postoperative Outcomes in People With and Without Alzheimer's Disease
Vu, Mai; Koponen, Marjaana; Taipale, Heidi; Kettunen, Raimo; Hartikainen, Sirpa; Tolppanen, Anna-Maija. 2021. Journals of gerontology series a: biological sciences and medical sciences. 76: 1524-1530 -
Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer's Disease
Pisa, Federica; Reinold, Jonas; Lavikainen, Piia; Koponen, Marjaana; Taipale, Heidi; Tanskanen, Antti; Tiihonen, Jari; Hartikainen, Sirpa; Tolppanen, Anna-Maija. 2021. Clinical epidemiology. 13: 295-307 -
Incidence of antidepressant use among community dwellers with and without Parkinson's disease - a nationwide cohort study
Hentilä, Eerik; Tiihonen, Miia; Taipale, Heidi; Hartikainen, Sirpa; Tolppanen, Anna-Maija. 2021. Bmc geriatrics. 21: 202 -
Incidence of cataract surgeries in people with and without Alzheimer's disease
Hokkinen, K; Kaarniranta, K; Jämsen, E; Lampela, P; Hartikainen, S; Tolppanen, AM. 2021. Acta ophthalmologica. 2022; 100: 68-73 -
Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders
Kuusimäki, Tomi; Al-Abdulrasul, Haidar; Kurki, Samu; Hietala, Jarmo; Hartikainen, Sirpa; Koponen, Marjaana; Tolppanen, Anna-Maija; Kaasinen, Valtteri. 2021. Movement disorders. 36: 1353-1361 -
Patient-reported outcomes in coronary artery disease: the relationship between the standard, disease-specific set by the International Consortium for Health Outcomes Measurement (ICHOM) and the generic health-related quality of life instrument 15D
Lappalainen, Laura; Stenvall, Harriet; Lavikainen, Piia; Miettinen, Heikki; Martikainen, Janne; Sintonen, Harri; Tolppanen, Anna-Maija; Roine, Risto P; Hartikainen, Juha. 2021. Health and quality of life outcomes. 19: 206